Product Image

Contributor Information

  • Name Anne Lykkesfeldt
  • Institute Danish Cancer Society

Tool Details

  • Tool name: MCF7/TAMR-8 Cell Line
  • Alternate names: MCF-7/TAMR-8; TAMR-8
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MCF7 S0.5
  • Organism: Human
  • Tissue: Breast
  • Gender: Female
  • Cancer type: Breast cancer
  • Disease: Cancer
  • Model: Tumour line
  • Conditional: Yes
  • Application: Investigate signalling pathways involved in tamoxifen
  • Description: MCF7/TAMR-8 cell line is a stable tamoxifen-resistant subline. This cell line has been established in tissue culture after long term treatment with 1 uM tamoxifen. Tamoxifen (Nolvadex) is a widely used drug for hormone-dependent cancer. Tamoxifen resistance (either primary or acquired) makes oestrogen receptor-positive breast cancer much more difficult to treat.

    This cell line was produced from the parental cell line MCF7/S0.5, as a model cell system to study the effects of tamoxifen resistant cancer growth. Tamoxifen-resistant cells are passaged continuously in the presence of 1 uM tamoxifen. This concentration is lethal for the parental cell line. MCF7/TAMR-8 cells are oestrogen receptor positive and progesterone receptor negative.

    Previous applications of this cell line include treatment with steroidal antioestrogens.

    MCF7/TAMR-8 enables identification of new hormone therapies and greater understanding of the signalling pathways/methods behind tamoxifen resistance. Additionally MCF/TAMR-8 can aid in identifying new predictive markers for response to hormonal therapy.
  • Research area: Cancer; Drug development
  • Production details: The parental cell line for the MCF7/TAMR-8 cells is MCF7/S0.5, which was adapted to grow at low serum concentration in order to study the effect of estradiol and tamoxifen. MCF7/TAMR-8 has been established from a clone of cells that survived long term treatment with 1 uM tamoxifen. Tamoxifen-resistant cells are passaged continuously in presence of 1 uM tamoxifen, which is lethal for the parental MCF7/S0.5 cell line.
  • Cellosaurus ID: CVCL_1D44
  • Additional notes: MCF7/TAMR-8 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-8 cells are growth inhibited by the pure antioestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-8 cell.

  • For Research Use Only

Target Details

  • Target: Oestrogen receptor

Application Details

  • Application: Investigate signalling pathways involved in tamoxifen
  • Application notes: MCF7/TAMR-8 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-8 cells are growth inhibited by the pure antioestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-8 cell. Passage 398 (AL2687, AL2688)

Handling

  • Format: Frozen
  • Passage number: Passage 398 (AL2687, AL2688)
  • Growth medium: Phenol red-free DMEM:Ham's F-12 containing 1% fetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 uM).
  • Temperature: 37° C
  • Atmosphere: 5% CO2
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

Related Tools

Product Image

MuCap4 [P379.1] CRPC Cell line

#161842
Product Image

CD6-GFP Jurkat cell line cell line

#160714
Product Image

PC346C 14 [BIC E] CRPC Cell line

#161824

References

  • •  Thrane et al. 2015. Oncogene. 34(32):4199-210. PMID: 25362855.
  • •  Elias et al. 2015. Oncogene. 34(15):1919-1927. PMID: 24882577.
  • •  Pedersen et al. 2014. Int J Oncol. 45(5):2167-2175. PMID: 25175082.
  • •  Lundqvist et al. 2014. Steroids. 85:30-35. PMID: 24747771.
  • •  Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.
  • •  Larsen et al. 2012. Int J Oncol. 41(5):1863-1870. PMID: 22961366.
  • •  Cutrupi et al. 2012. Oncogene. 31(40):4353-4361. PMID: 22249258.
  • •  Frankel et al. 2007. Breast Cancer Res Treat. 104(2):165-179. PMID: 17061041.
  • •  Beliakoff et al. 2003. Clin Cancer Res. 9(13):4961-4971. PMID: 14581371.
  • •  Madsen et al. 1995. Mol Cell Endocrinol. 109(2):197-207. PMID: 7664983.